Condition: Severe Hemophilia A · Severe Hemophilia A With Inhibitor · Severe Hemophilia A Without Inhibitor · Sponsor: Christoph Königs
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
This description comes directly from the study's public registry record.
Stephan Schultze-Strasser, Dr. · +496963016998 · stephan.schultze-strasser@kgu.de
Christoph Koenigs, PD Dr. Dr · +4969630183030 · christoph.koenigs@kgu.de
Always discuss trial participation with your own doctor first.
| University Hospital Frankfurt, Goethe University | Frankfurt am Main, Hesse, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05802836